Last Updated : July 24, 2024
Details
Generic Name:
galcanezumab
Project Status:
Not filed
Therapeutic Area:
Episodic cluster headache
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Emgality
Project Line:
Reimbursement Review
Project Number:
NS0019-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
The reduction in the frequency of attacks throughout a cluster period in adults with episodic cluster headache with prior cluster headache periods lasting at least 6 weeks and who have had an inadequate response to, or tolerated poorly, or had contraindications to conventional preventive therapies established by Canadian practice guidelines.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024